IMCgp100-401 Rollover Study
An Open-label, Multi-center, Rollover Study in Patients With Advanced Melanoma After Completing an IMCgp100 Clinical Study
Sponsor: Immunocore Ltd
Terminated
Sponsor decision
Other terminated trials from Immunocore Ltd
More terminations from Immunocore Ltd
Other Malignant Melanoma trials with similar outcome
This PHASE2 trial investigates Malignant Melanoma and is currently terminated or withdrawn. Immunocore Ltd leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2019 — Aug 2020 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Jul 2019 — Sep 2019 [monthly]
Terminated PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Apr 2017 — Apr 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Immunocore Ltd
For direct contact, visit the study record on ClinicalTrials.gov .